A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer; CA209-7DX;

Condition: | Last Updated: 4 Apr 21 | Status: enrolling

View Full Study